FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease

Reuters12-02

FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease

Ionis Pharmaceuticals Inc. has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for zilganersen, an investigational treatment for Alexander disease (AxD). This designation is granted to therapies that treat serious or life-threatening conditions and have shown preliminary clinical evidence of substantial improvement over existing treatments. Zilganersen demonstrated statistically significant and clinically meaningful results in a pivotal study, including stabilization of gait speed in affected patients. Ionis plans to submit a New Drug Application (NDA) to the FDA in the first quarter of 2026 and is preparing to initiate an Expanded Access Program in the U.S. There are currently no approved disease-modifying treatments for Alexander disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202774475) on December 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588306240?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588306240","market":"fut","top_or_hot":-1,"title":"FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ionis Pharmaceuticals Inc. has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for zilganersen, an investigational treatment for Alexander disease (AxD). This designation is granted to therapies that treat serious or life-threatening conditions and have shown preliminary clinical evidence of substantial improvement over existing treatments. Zilganersen demonstrated statistically significant and clinically meaningful results in a pivotal study, including stabilization of gait speed in affected patients. Ionis plans to submit a New Drug Application (NDA) to the FDA in the first quarter of 2026 and is preparing to initiate an Expanded Access Program in the U.S. There are currently no approved disease-modifying treatments for Alexander disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202774475) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-02 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ionis Pharmaceuticals Inc. has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for zilganersen, an investigational treatment for Alexander disease (AxD). This designation is granted to therapies that treat serious or life-threatening conditions and have shown preliminary clinical evidence of substantial improvement over existing treatments. Zilganersen demonstrated statistically significant and clinically meaningful results in a pivotal study, including stabilization of gait speed in affected patients. Ionis plans to submit a New Drug Application (NDA) to the FDA in the first quarter of 2026 and is preparing to initiate an Expanded Access Program in the U.S. There are currently no approved disease-modifying treatments for Alexander disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202774475) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL2QRdNf:1","article_id":"2588306240","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588306240","pubTimestamp":1764676832,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ionis Pharmaceuticals Inc. has received Breakthrough Therapy designation from the U.S. Food and Drug Administration  for zilganersen, an investigational treatment for Alexander disease . This designation is granted to therapies that treat serious or life-threatening conditions and have shown preliminary clinical evidence of substantial improvement over existing treatments. Zilganersen demonstrated statistically significant and clinically meaningful results in a pivotal study, including stabilization of gait speed in affected patients. Ionis plans to submit a New Drug Application  to the FDA in the first quarter of 2026 and is preparing to initiate an Expanded Access Program in the U.S. There are currently no approved disease-modifying treatments for Alexander disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"FDA授予Ionis Pharmaceuticals的Zilganersen治疗亚历山大病的突破性疗法认定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":0.9},"content_text":"FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease\n    \n\n        Ionis Pharmaceuticals Inc. has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for zilganersen, an investigational treatment for Alexander disease (AxD). This designation is granted to therapies that treat serious or life-threatening conditions and have shown preliminary clinical evidence of substantial improvement over existing treatments. Zilganersen demonstrated statistically significant and clinically meaningful results in a pivotal study, including stabilization of gait speed in affected patients. Ionis plans to submit a New Drug Application (NDA) to the FDA in the first quarter of 2026 and is preparing to initiate an Expanded Access Program in the U.S. There are currently no approved disease-modifying treatments for Alexander disease.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202774475) on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588306240","isCrawlerRequest":true}